Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bone and Joint Infection
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 23
- Primary Endpoint
- Typical daptomycin clearance
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines.
The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint infections (BJI). Also, previous population studies did not investigate daptomycin PK over prolonged therapy, and, to our knowledge, no study has reported the intraindividual PK variability of this drug.
The aim of this study is to describe the inter- and intraindividual PK variability of this drug.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients treated with daptomycin for BJI in Lyon Center in 2012 and 2013
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Typical daptomycin clearance
Time Frame: 6 months
Mean daptomycin plasma clearance (unit, liters per hour) Outcome measures performed regularly in those patients throughout therapy, roughly every month.
Typical daptomycin volume of distribution
Time Frame: 6 months
Mean daptomycin volume of distribution (unit, liters) in the population